347 results about "Atheromatosis" patented technology

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

This disclosure relates to systems, methods, and devices for plaque analysis, vessel and fluid flow analysis, and / or risk determination or prediction thereof. Some embodiments relate to determining fractional flow reserve (FFR) values. Some embodiments relate to determining FFR values using 3D-printed models. Some embodiments relate to identifying thin cap fibroatheroma based on analysis of computed tomography (CT) imaging. Some embodiments relate adjusting calcified plaque thresholds for CT images to address effects of calcium blooming.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

The invention relates to the technical field of biological medicines, and provides a self-assembled polypeptide-rhein conjugate, a preparation as well as a preparation method and application of the self-assembled polypeptide-rhein conjugate. The sequence of the MMP-9 responsive self-assembled polypeptide-rhein conjugate is Rhein-GFFPLGLAGACE, and the MMP-9 responsive self-assembled polypeptide-rhein conjugate can respond to abnormally activated MMP-9 in atherosclerotic plaque and is self-assembled into a stable nanofiber structure in situ at a diseased region; the anti-inflammatory and anti-oxidation functions of rhein in the conjugate are remarkable, but the water solubility and oral bioavailability are low, the anti-inflammatory and anti-oxidation functions are remarkably improved after being coupled with the polypeptide, targeted delivery is achieved, and the residence time is prolonged; the introduction of the tripeptide ACE simulating the function of glutathione further enhances the oxidative stress resistance of the conjugate. Furthermore, the conjugate shows excellent anti-inflammatory and anti-oxidation effects, can clear ROS, inhibit inflammation pathways, regulate macrophage phenotypes and inhibit apoptosis, and provides a new strategy for treatment of atherosclerosis.

The invention discloses an atherosclerotic plaque risk assessment method and system based on artificial intelligence, relates to the technical field of medical image analysis, and provides the following scheme: synchronously acquiring medical image sequence and physiological signal time sequence data, generating a synchronization data set through time-space registration, and performing time-space registration on the synchronization data set; and inputting the synchronized data set into a pre-trained LSTM neural network, and outputting a dynamic artifact offset field which represents a displacement vector of a medical image pixel point along with a physiological signal phase. Gradient amplitude analysis is performed on the medical image sequence frame by frame to generate the gradient characteristic evolution graph, high, medium and low response areas are divided according to the dynamic gradient threshold interval, and the displacement correction vectors are configured for the areas, so that the problem of gradient response heterogeneity compensation deficiency in a conventional correction strategy is solved, adaptive deformation correction of an anatomical structure is realized, and the correction accuracy is improved. And low-gradient region structure dispersion and vascular wall edge sharpness attenuation caused by global compensation are inhibited.

The application discloses a method for constructing a mouse model of atherosclerosis induced without high-fat diet, and relates to the technical field of disease model construction.The mouse model construction method provided by the application obtains a mouse model that spontaneously exhibits atherosclerosis symptoms without high-fat diet induction.The mouse model of atherosclerosis induced without high-fat diet can be used for researching the pathogenesis of atherosclerosis and screening and evaluating drugs for atherosclerosis.

Compositions and method of increasing levels of apoA1 and / HDL in a subject in need thereof are provided. The compositions include one or more TLR5 agonists in a pharmaceutically acceptable carrier in an effective amount to increase the level of apoA1 and / or HDL in a subject. In a preferred embodiment, the composition is an oral formulation of the one or more TLR5 agonists. The disclosed methods include administering compositions containing the one or more TLR5 agonists to a subject in need thereof, in an effective amount to increase levels of apoA1 and / or HDL in the subject. In one preferred embodiment, the subject is at risk of developing atherosclerosis and / or coronary heart disease. In some embodiments, the subject is diagnosed as having atherosclerosis. The disclosed compositions can also be administered to subjects presenting with hyperlipidemia or hypercholesterolemia.

The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and / or phosphatidylserine content. The present disclosure describes technologies useful for the treatment of inflammatory diseases, disorders, or conditions (e.g., atherosclerosis).

Provided herein are engineered T cell receptor (TCR) proteins, nucleic acids, vectors, host cells, methods of treating atherosclerosis-related autoimmune disease, and chimeric antigen receptor expressing T cell (CAR-T) comprising a beta chain CDR3 selected from the amino acid sequence of SEQ ID NOS: 179 to 356 and an alpha chain, wherein the TCR is specific for a human apolipoprotein B (ApoB) epitope, antigen-MHC binding portions, and full-length versions of the same.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention discloses an MKP7 targeted bionic nanoparticle preparation as well as a preparation method and application thereof. The MKP7 targeted bionic nanoparticle preparation is a bionic nanoparticle siMKP7 (at) NP-M-pHLIP, wherein the bionic nanoparticle siMKP7 (at) NP-M-pHLIP is coated with a macrophage membrane modified by pHLIP and is loaded with siMKP7. According to the preparation, a PLGA-PEI copolymer is used as a carrier core to wrap siMKP7, an outer layer is coated with a macrophage membrane, the surface of the membrane is modified with pHLIP targeting peptide, and spherical nanoparticles with bionic camouflage and pH sensitive targeting delivery functions are constructed. In-vitro experiments show that the nanoparticles can be effectively ingested by macrophages, and macrophage lipid deposition induced by ox-LDL is remarkably inhibited; in-vivo experiments prove that the preparation can be delivered to atherosclerotic plaque parts in a targeted manner, and by inhibiting expression of MKP7 in macrophages, the carotid plaque area is effectively reduced, the serum inflammatory factor level is reduced, and the blood lipid metabolism is regulated, so that development of atherosclerosis is inhibited, and the curative effect of atherosclerosis is improved. A high-efficiency and low-toxicity nucleic acid drug delivery system is provided for treatment of atherosclerosis.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None

The invention discloses rosa roxburghii tratt black tea and a preparation method thereof. The rosa roxburghii tratt black tea is prepared from the following raw materials in parts by weight: 120-150 parts of palmtop ancient tree black tea, 50-100 parts of rosa roxburghii tratt and 3-5 parts of pseudo-ginseng. Selecting fresh wild rosa roxburghii tratt; the method comprises the following steps: cleaning fresh wild raw rosa roxburghii tratt fruits, removing thorns and impurities on the surfaces, and draining water; drying until the water content is 10-15%, and selecting high-quality Pankg ancient tree black tea for later use; slightly crushing pseudo-ginseng into coarse particles for later use; and weighing the dried wild rosa roxburghii tratt, the stir-fried Panku ancient tree black tea and the pseudo-ginseng coarse particles according to the ratio, putting the weighed materials into a tea bag, and packaging the product. The formula disclosed by the invention is brewed with boiling water at the temperature of 90 DEG C or above, the first time of soaking lasts for 6-30 minutes preferably, the later time of soaking lasts for 3-15 minutes preferably, and the beverage can be drunk after being soaked. The traditional Chinese medicine composition has the functions of enhancing body immunity, delaying senescence, resisting atherosclerosis and tumors, invigorating stomach, resisting stress, protecting pancreas, preventing and treating diabetes and the like, and has a certain detoxification effect on metals such as lead, fluorine, manganese, mercury and cadmium.

The invention provides a white flower salvia miltiorrhiza composition and application thereof in medicines for preventing and treating atherosclerosis, and belongs to the technical field of traditional Chinese medicines. According to the technical scheme, the composition is characterized by comprising 3-5 parts of white flower salvia miltiorrhiza root slices, 1-2 parts of white flower salvia miltiorrhiza dried leaves and 1-2 parts of white flower salvia miltiorrhiza extract. Mixing the white flower salvia miltiorrhiza leaf powder with a malic acid aqueous solution, carrying out ultrasonic treatment, filtering, and carrying out alcohol precipitation on filtrate to obtain an alcohol precipitate; extracting the white flower salvia miltiorrhiza root powder by using supercritical carbon dioxide to obtain a supercritical extract; mixing the alcohol precipitate and the supercritical extract according to the weight ratio of (7-9): (1-3) to obtain a white flower salvia miltiorrhiza extract; the alcohol used in the alcohol precipitation is methanol; methyl acetate is used as an entrainer in the supercritical carbon dioxide extraction. The white flower salvia miltiorrhiza composition provided by the invention has the beneficial technical effect of remarkably improving atherosclerosis.

The invention relates to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for reducing the content of cholesterol in blood and a preparation method and application thereof. The traditional Chinese medicine composition for reducing the cholesterol content in the blood is prepared from the following raw material medicines in parts by weight: 3-6 parts of black beans, 1-3 parts of vegetables and 0.1-0.3 part of walnuts. The vegetables are selected from spinach or a combination of asparagus and pumpkins; wherein the black beans are black-peel and yellow-kernel varieties, the anthocyanin content is more than or equal to 2.5 mg / g, and the total amount of soy isoflavone is more than or equal to 4.0 mg / g; the spinach is an overwintering variety, and the proportion of soluble dietary fibers is greater than or equal to 16%; according to the traditional Chinese medicine composition for reducing the content of cholesterol in blood, active ingredients such as anthocyanin, isoflavone, unsaturated fatty acid and the like of black beans are fully utilized and have a synergistic effect with dietary fibers and vitamins of specific vegetables, the activity of thermosensitive ingredients is reserved by optimizing a process, the blood cholesterol is effectively reduced, and the traditional Chinese medicine composition is safe, free of side effects, low in cost and suitable for industrial production. The traditional Chinese medicine composition is suitable for prevention or adjuvant treatment of hypercholesteremia and atherosclerosis.

The invention relates to the technical field of biological medicine, in particular to a TREM-1 targeted fluorescent molecular probe as well as a preparation method and application thereof, and discloses a fluorescent molecular probe named as' TREM-1 targeted fluorescent molecular probe as well as a preparation method and application thereof '. The invention aims to solve the problems of large molecular weight, poor pharmacokinetic performance, limited tissue penetration, high imaging background and poor imaging timeliness of the existing antibody fluorescent probe. The probe comprises a TREM-1 targeting module (TDM), a near-infrared fluorescence reporter group, a dark quenching group and a conformational sensitive connecting arm (CSL). The fluorescence of the probe is quenched before the probe is combined with TREM-1, and after the probe is combined with a target spot, TDM specific binding induces CSL conformation rearrangement, so that a reporter group and a quenching group are spatially separated, fluorescence resonance energy transfer (FRET) is relieved, and fluorescence activation is realized. According to the invention, rapid, high-contrast and low-background fluorescence imaging of atherosclerotic plaques is realized, and the probe is small in molecular size, strong in tissue penetrability and rapid in-vivo clearing.

Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating cardiovascular disease, hypertension and / or atherosclerosis.

The application relates to the technical field of organic fluorescent probes, and particularly discloses a lipid droplet and hypochlorous acid sequence response type fluorescent probe, a structural formula of which is as shown in the figure; wherein R is a cyano group, a benzothiazole group, a benzimidazole group, an amido group, an ethoxycarbonyl group or an acetyl group. The precise imaging lipid droplet and hypochlorous acid sequence response fluorescent probe of the application takes a phenothiazine-coumarin dye support as a matrix, utilizes a double trifluoromethyl benzyl group as a lipid droplet targeting group, adjusts the dye emission wavelength by introducing different electron-withdrawing groups, synthesizes a series of probes, and realizes high-targeting sequence imaging of lipid droplets and hypochlorous acid in atherosclerotic plaques.

The present invention provides a method of increasing glycemic control in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method of improving body weight management in a patient in need thereof by administering tizatide, or a pharmaceutically acceptable salt thereof. Also provided is a method of treating a condition selected from the group consisting of atherosclerosis, chronic kidney disease, NAFLD and NASH. Also provided is a method of preventing or causing alleviation of diabetes mellitus, comprising administering tizatide or a pharmaceutically acceptable salt thereof. Also provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The application discloses a kind of near-infrared afterglow nano probe and its preparation method and application, wherein the near-infrared long afterglow nano probe is near-infrared long afterglow nano probe, particle size is 100nm, and its composition is: ZnGaSnO4:Cr, Y, wherein, the ratio of Zn, Ga, Sn, Cr, Y is 1.3:1.4:0.3:0.005:0.003, the near-infrared long afterglow nano probe of the application has higher luminous intensity and excellent fluorescent performance, is a new type of luminescent material, can emit light for more than several hours under external environment, has high luminous intensity, long life and good chemical stability and other characteristics, has the advantages of low background, strong fluorescent signal, high signal-to-noise ratio and the like, label is connected with oxidized low density lipoprotein monoclonal antibody by covalent bond, and the labeled product is stable, has the characteristics of high sensitivity, high accuracy, rapid and simple detection and the like, early diagnosis, curative effect monitoring and prognosis evaluation of coronary heart disease and atherosclerosis can quickly help clinical diagnosis.

This invention discloses a therapeutic molecule, nanoparticles, and their preparation method for locating and stabilizing atherosclerotic plaques. The therapeutic molecule is synthesized based on cholanonic acid and copper peptide, and the nanoparticles are formed by the self-assembly of the therapeutic molecule. The preparation method involves aldehyde modification of both ends of cholanonic acid and coupling it with copper peptide via a Schiff base reaction to obtain a therapeutic molecule with both diagnostic and therapeutic functions. The copper peptide structure in the therapeutic molecule serves as the hydrophilic segment, and the cholanonic acid structure serves as the hydrophilic segment, allowing it to further self-assemble into nanoparticles in water. These nanoparticles exhibit acid responsiveness and can disintegrate in the slightly acidic environment of atherosclerotic sites. The released copper peptide can stabilize plaques by promoting collagen secretion and inhibiting matrix metalloproteinase expression. Simultaneously, the X-ray imaging characteristics of cholanonic acid can be used to locate and diagnose the distribution of plaques, thus achieving integrated stabilization and localization of atherosclerotic plaques.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention discloses a traditional Chinese medicine composition with effects of reducing blood fat and resisting carotid atherosclerotic plaque and a preparation method of the traditional Chinese medicine composition. The composition is innovatively cut by taking eight-treasure soup as a basic framework, and comprises American ginseng, astragalus membranaceus, lucid ganoderma, saffron crocus extract, saussurea involucrata culture, donkey-hide gelatin, angelica sinensis, prepared rehmannia root, peach kernel, hawthorn, semen cassiae, lotus leaf, mulberry leaf, dandelion, hovenia dulcis thunb, kudzu vine root, radix polygonati officinalis, poria cocos, coix seed, orange peel, fructus amomi and honey-fried licorice root. American ginseng is used for replacing ginseng, radix astragali is used for reinforcing qi tonifying, saffron crocus, peach kernels, hawthorn fruits and the like are matched for reinforcing blood circulation promoting and blood stasis removing, semen cassiae, lotus leaves and other medicine groups for clearing heat, reducing phlegm and descending turbidity are added, and meanwhile fructus amomi and orange peel are used for strengthening the spleen and regulating qi. The traditional Chinese medicine composition has the effects of supporting the healthy energy and treating phlegm and blood stasis on the pathogenesis of qi-blood deficiency and phlegm and blood stasis, and has a synergistic enhancement effect on the aspects of reducing blood fat and inhibiting atherosclerotic plaque.

The invention discloses a radioactive diagnosis medicine for targeting OPN as well as a preparation method and application of the radioactive diagnosis medicine. The radioactive diagnosis medicine comprises linear polypeptide and radionuclide, wherein the linear polypeptide is composed of 20 L-type amino acids and one D-type amino acid, and the radionuclide marks the linear polypeptide through a bifunctional chelating agent; the sequence of the linear polypeptide is as shown in SEQ ID NO. 1. In vivo, radionuclides in the medicine are concentrated to an atherosclerotic vulnerable plaque part through the targeting effect of the amino acid linear polypeptide, and imaging diagnosis is carried out on the atherosclerotic vulnerable plaque by utilizing a positron emission computed tomography technology of nuclear medicine.

This invention relates to ONOO ‑ In the field of detection technology, specifically involving an ONOO ‑ Near-infrared fluorescent probe, its preparation method, and its application. This invention constructs a novel fluorescent probe specifically for detecting ONOO. ‑ The ONOO ‑ Near-infrared fluorescent probe for ONOO ‑ It exhibits good reactivity and is capable of specifically imaging endogenous ONOO in living cells or in vivo systems. ‑ Furthermore, it exhibits a large Stokes shift and an emission wavelength of 760 nm, significantly higher than other near-infrared fluorescent probes based on hemicyanine dye structures. In addition, this ONOO... ‑ The near-infrared emission characteristics of near-infrared fluorescent probes enable them to penetrate deeper into tissues and reduce background interference in bioimaging, which is significant for improving imaging sensitivity and accuracy. Based on these characteristics, ONOO... ‑ Near-infrared fluorescent probes can be used for the diagnosis and research of diseases such as atherosclerosis, neurodegenerative diseases, inflammation, and cancer.

This disclosure relates to anti-human CD154 antibodies with modified effector function. This disclosure also relates to the use of these anti-human CD154 antibodies in treating conditions associated with CD154 activation, such as transplant rejection, inflammatory conditions and disease, dysfunctional immune responses associated with viral infections and diseases, autoimmune conditions and disease, allergic conditions, atherosclerotic conditions, or neurodegenerative conditions and diseases. It also relates to the use of these anti-human CD154 antibodies in inducing central tolerance and hematopoietic chimerism in transplant patients.